Regarding its pro-tumorigenic role, mouse models of CRC, have demonstrated that pharmacological inhibition of extracellular GzmA reduces gut inflammation, prevents CRC development, and epithelial-to-mesenchymal transition (230). This evidence concerns the gene GZMA and colorectal carcinoma.